EP4573371A4 - Diagnose und behandlung von akuter nierenläsion - Google Patents

Diagnose und behandlung von akuter nierenläsion

Info

Publication number
EP4573371A4
EP4573371A4 EP23855713.6A EP23855713A EP4573371A4 EP 4573371 A4 EP4573371 A4 EP 4573371A4 EP 23855713 A EP23855713 A EP 23855713A EP 4573371 A4 EP4573371 A4 EP 4573371A4
Authority
EP
European Patent Office
Prior art keywords
lession
diagnosis
treatment
acute kidney
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23855713.6A
Other languages
English (en)
French (fr)
Other versions
EP4573371A2 (de
Inventor
Chirag Parikh
Yumeng Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4573371A2 publication Critical patent/EP4573371A2/de
Publication of EP4573371A4 publication Critical patent/EP4573371A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP23855713.6A 2022-08-19 2023-08-18 Diagnose und behandlung von akuter nierenläsion Pending EP4573371A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263371894P 2022-08-19 2022-08-19
PCT/US2023/072477 WO2024040225A2 (en) 2022-08-19 2023-08-18 Diagnosis and treatment of acute kidney injury

Publications (2)

Publication Number Publication Date
EP4573371A2 EP4573371A2 (de) 2025-06-25
EP4573371A4 true EP4573371A4 (de) 2026-08-12

Family

ID=89942325

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23855713.6A Pending EP4573371A4 (de) 2022-08-19 2023-08-18 Diagnose und behandlung von akuter nierenläsion

Country Status (2)

Country Link
EP (1) EP4573371A4 (de)
WO (1) WO2024040225A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118899088B (zh) * 2024-10-09 2025-01-21 山东中医药大学附属医院 一种脓毒症早期风险的预测系统和方法
CN120829482B (zh) * 2025-09-15 2026-02-10 吉林农业大学 一种抑制铁死亡的活性肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153863B1 (de) * 2009-11-07 2020-04-01 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von akutem nierenversagen/akuter nierenschädigung
US20200124614A1 (en) * 2018-10-03 2020-04-23 Yale University Compositions and Methods for Assessing Acute Kidney Injury (AKI) and Mortality Risk
US20200150132A1 (en) * 2010-09-24 2020-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers of renal injury
WO2021204910A1 (en) * 2020-04-07 2021-10-14 Sciomics Gmbh Prediction and early diagnosis of acute kidney injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153863B1 (de) * 2009-11-07 2020-04-01 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von akutem nierenversagen/akuter nierenschädigung
US20200150132A1 (en) * 2010-09-24 2020-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US20200124614A1 (en) * 2018-10-03 2020-04-23 Yale University Compositions and Methods for Assessing Acute Kidney Injury (AKI) and Mortality Risk
WO2021204910A1 (en) * 2020-04-07 2021-10-14 Sciomics Gmbh Prediction and early diagnosis of acute kidney injury

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL-GHAMDI MARYAM A ET AL: "Serum proteins C and S levels as early biomarkers for kidney dysfunction in hemophilic patients", AFRICAN HEALTH SCIENCES, vol. 18, no. 3, 15 August 2018 (2018-08-15), UG, pages 681, XP093411601, ISSN: 1680-6905, DOI: 10.4314/ahs.v18i3.26 *
HIDAWA ERIKA ET AL: "Incidence, Risk Factors, and Outcomes of Neonatal AKI in Very Low Birth Weight Infants: A Retrospective Cohort Study in a Single Neonatal Intensive Care Unit in Japan", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 33, no. 11S, 1 November 2022 (2022-11-01), Hagerstown, MD, pages 358 - 358, XP093411086, ISSN: 1046-6673, DOI: 10.1681/asn.20223311s1358a *
KITCHING A. RICHARD ET AL: "Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 5, 3 March 1997 (1997-03-03), New York, NY, pages 963 - 968, XP093411559, ISSN: 0022-1007, DOI: 10.1084/jem.185.5.963 *
LEVIN ANNA ET AL: "Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 35, no. 12, 27 August 2020 (2020-08-27), pages 2059 - 2072, XP093411090, ISSN: 0931-0509, DOI: 10.1093/ndt/gfaa121 *
MORITA JUNKO ET AL: "Structure and biological function of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase", SCIENTIFIC REPORTS, vol. 6, no. 1, 18 February 2016 (2016-02-18), US, XP093411553, ISSN: 2045-2322, DOI: 10.1038/srep20995 *
SCHNAPER H. WILLIAM ET AL: "TGF-beta signal transduction in chronic kidney disease", FRONTIERS IN BIOSCIENCE, vol. Volume, no. 14, 1 January 2009 (2009-01-01), US, pages 2448, XP093411436, ISSN: 1093-9946, DOI: 10.2741/3389 *
WEN YUMENG ET AL: "Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury", SCIENCE TRANSLATIONAL MEDICINE, vol. 15, no. 726, 13 December 2023 (2023-12-13), XP093411081, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.ade7287 *
XU FUJIANG ET AL: "The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma", SCIENTIFIC REPORTS, vol. 7, no. 1, 29 August 2017 (2017-08-29), US, XP093411435, ISSN: 2045-2322, DOI: 10.1038/s41598-017-10134-2 *

Also Published As

Publication number Publication date
WO2024040225A2 (en) 2024-02-22
EP4573371A2 (de) 2025-06-25
WO2024040225A9 (en) 2024-05-02
WO2024040225A3 (en) 2024-03-28

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250318

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260706

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20260703BHEP

Ipc: G01N 33/487 20060101ALI20260703BHEP

Ipc: G01N 33/50 20060101ALI20260703BHEP

Ipc: C12Q 1/6883 20180101ALI20260703BHEP